Celebrating 20 Years of IP Excellence

Diabetic Product XIGAMET loses to ZITAMET under heightened Pharma Trademark Scrutiny

Diabetic Product XigaMet Loses to ZitaMet Under Heightened Pharma Trademark Scrutiny

On June 13, 2024, the Bombay High Court granted Glenmark an interim injunction against Gleck Pharma in a trademark dispute over “ZITA-MET” and “XIGAMET”. The court found that the similarities between the trademarks could confuse consumers, leading to potential health risks, and applied strict standards to prevent such confusion. Continue Reading Diabetic Product XigaMet Loses to ZitaMet Under Heightened Pharma Trademark Scrutiny

Read more

Image accompanying blogpost on "Glaxo's BETNESOL vs Zee's BETNEVIN : Who do you BET on?"

Glaxo’s BETNESOL vs Zee’s BETNEVIN : Who do you BET on?

The Delhi High Court enforced a decree favoring Glaxo Group Limited against Mr. Rajiv Mukul, restraining the use of ‘BETNEVIN’ due to trademark infringement of ‘BETNESOL’. The Court upheld that infringement determination could be made in an execution petition to enforce the decree of injunction. Continue Reading Glaxo’s BETNESOL vs Zee’s BETNEVIN : Who do you BET on?

Read more